Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Hepatitis a vaccine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Havrix Junior Monodose is a vaccine containing the hepatitis A virus. It is used to boost the body's immune system to help protect against hepatitis A infection in children and adolescents from 1 year up to and including 15 years of age. How Havrix Junior Monodose works
2 What you need to know before your child receives Havrix Junior Monodose Havrix Junior Monodose should not be given if:
-1-
• •
your child is aged 16 years or over, as another product, Havrix Monodose is recommended for this age group your child has a high temperature (fever). The presence of a minor infection such as a cold should not be a problem. Talk to your doctor first.
Do not give your child Havrix if any of the above apply to them. If you are not sure, talk to their doctor, nurse or pharmacist before they have Havrix. Warnings and precautions Check with the doctor, nurse or pharmacist before Havrix Junior Monodose is given if:
-2-
This medicine contains less than 1 mmol sodium (23 mg) per 1 mL dose, that is to say essentially 'sodium-free'. This vaccine contains 83 micrograms of phenylalanine in each dose. Phenylalanine may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
3 • • • • • • • • •
4
Havrix Junior Monodose is for use in children and adolescents from 1 year up to and including 15 years of age. Adolescents 16 years and above should receive Havrix Monodose. A single dose of 0.5 mL is injected into the muscle in the upper arm or thigh. The vaccine should never be given into the buttock. The vaccine should never be given into a vein. The first dose of vaccine should protect your child from infection with hepatitis A virus within 2 to 4 weeks. Protection should last for at least 1 year. The best way to ensure that protection continues for at least 10 years is to receive a second (booster) dose of the vaccine. This should be given 6 to 12 months after the first injection. If the date for the booster injection is missed but a second dose is given within 3 years of the first dose, protection against hepatitis A infection should still continue for at least 10 years. If a second dose is not given within 3 years of the first dose, the doctor may decide that vaccination should start again, with 2 doses of vaccine within 1 year.
Possible side effects
Like all medicines, this vaccine can have side effects, although not everybody gets them. Allergic reactions (these may occur with up to 1 in 10,000 doses of the vaccine) See your doctor straight away, if your child has an allergic reaction. The signs may include:
-3-
• • •
Swelling or hard lump at the injection site Generally feeling unwell Fever
Uncommon (these may occur with up to 1 in 100 doses of the vaccine):
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5 • • • • • •
6
Havrix Junior Monodose Keep out of the sight and reach of children. Store between 2 °C and 8 °C in a refrigerator. Do not freeze. Store in the original package with this leaflet in order to protect from light. Do not use after the expiry date which is stated on the label and carton. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Havrix Junior Monodose contains
-4-
•
The active ingredient is inactivated hepatitis A virus. Each 0.5 mL dose of the vaccine contains 720 ELISA units of hepatitis A viral protein, adsorbed on aluminium hydroxide, hydrated.
•
The other ingredients are polysorbate 20, amino acids for injection (containing phenylalanine), disodium phosphate, monopotassium phosphate, sodium chloride, potassium chloride and water for injections.
What Havrix Junior Monodose looks like and contents of the pack Havrix Junior Monodose is a cloudy white injectable liquid vaccine. Havrix Junior Monodose is available in 1-dose pre-filled syringe that contains a single 0.5 ml dose. The vaccine is available in packs of 1 or 10 pre-filled syringes. Marketing Authorisation Holder and Manufacturer Marketing Authorisation holder: SmithKline Beecham Ltd, 79 New Oxford Street, London WC1A 1DG United Kingdom Manufacturer: GlaxoSmithKline Biologicals s.a., Rixensart, Belgium. Other formats: To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:
0800 198 5000 (UK only). Please be ready to give the following information: Product name Havrix Junior Monodose Reference number 10592/0080 This is a service provided by the Royal National Institute of Blind People. This leaflet was last revised in November 2024 Trade marks are owned by or licensed to the GSK group of companies. © 2024 GSK group of companies or its licensor.
Instructions for the pre-filled syringe
Luer Lock Adaptor Hold the syringe by the barrel, not by the plunger. Unscrew the syringe cap by twisting it anticlockwise.
Plunger Barrel Cap
-5-
Needle hub
To attach the needle, connect the hub to the Luer Lock Adaptor and rotate a quarter turn clockwise until you feel it lock. Do not pull the syringe plunger out of the barrel. If it happens, do not administer the vaccine.
Disposal Any unused product or waste material should be disposed of in accordance with local requirements. General information on hepatitis A Hepatitis A virus causes an infection of the liver. You can catch the virus by eating or drinking contaminated food or water. The virus is present in the bowel movement (motion) of infected people, even when they may have no signs of the infection. You can catch hepatitis A infection in any country but the risk is highest in places and countries where sanitation and food and water hygiene are poor. After catching the virus, it can be up to 6 weeks before signs of illness are seen. Some people have the virus and never get ill but they can still infect other people during this time. The main signs of the illness include sickness, yellowing of the skin and eyes (jaundice), fever and headache. These signs are all due to an inflammation of the liver while it is infected with the virus. Most patients get better, usually after a couple of weeks or months, but a few people may take up to a year to make a full recovery. While recovering, people affected with hepatitis A may be unable to work. They may not be able to drink alcohol and may need to avoid certain foods according to their doctors' advice. Severe complications are very rare but sometimes the liver stops working and hospital care is needed until the infection gets better. There are many other types of virus that can cause hepatitis. The signs may be the same as in hepatitis A infection but the viruses are not always caught through food and drink.
-6-
The active substance in Havrix Junior Monodose Vaccine is hepatitis a vaccine.
Medicines with the same active substance, strength and form include: Havrix Monodose Vaccine. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Havrix Junior Monodose Vaccine, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Active immunisation against HAV infection from 1 year up to and including 15 years of age.
The vaccine is particularly indicated for those at increased risk of infection or transmission. It is also indicated for use during outbreaks of hepatitis A infection.
Posology
Children/adolescents (1-15 years)
Primary immunisation consists of a single dose given intramuscularly. This provides anti-HAV antibodies for at least one year.
This vaccine confers protection against hepatitis A within two to four weeks.
In order to obtain more persistent immunity, for at least 10 years, a booster dose is recommended between 6 and 12 months after primary immunisation.
Booster vaccination delayed up to 3 years after the primary dose induces similar antibody levels as a booster dose administered within the recommended time interval.
Current recommendations do not support the need for further booster vaccination among immunocompetent subjects after a 2-dose vaccination course (see section 5.1).
Havrix Junior Monodose can be used as a booster in subjects previously immunised with any inactivated hepatitis A vaccine.
In the event of a subject being exposed to a high risk of contracting hepatitis A within two weeks of the primary immunisation dose, human normal immunoglobulin may be given simultaneously with this vaccine at different injection sites.
Method of administration
The vaccine should be injected intramuscularly in the deltoid region or into the antero-lateral part of the thigh in young children. The vaccine should not be administered in the gluteal region.
The vaccine should never be administered intravascularly.
The vaccine should not be administered subcutaneously/intradermally since administration by these routes may result in a less than optimal anti-HAV antibody response. In subjects with a bleeding disorder who are at risk of haemorrhage following intramuscular injection (e.g. haemophiliacs), this vaccine may be administered by deep subcutaneous injection as per local guidance. Firm pressure should be applied to the injection site (without rubbing) for at least two minutes.
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to neomycin (present at traces).
Immunisation should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.
As for all vaccines, appropriate medication e.g.epinephrine (adrenaline) should be readily available for immediate use in case of anaphylaxis.
It is possible that subjects may be in the incubation period of a hepatitis A infection at the time of immunisation. It is not known whether Havrix Junior Monodose will prevent hepatitis A in such cases.
In haemodialysis patients and in subjects with an impaired immune system, adequate anti-HAV antibody titres may not be obtained after the primary immunisation and such patients may therefore require administration of additional doses of vaccine.
Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.
Excipients
This vaccine contains 83 micrograms of phenylalanine in each dose. Phenylalanine may be harmful to patients that have phenylketonuria (PKU).
This medicine contains potassium, less than 1 mmol (39 mg) per 0.5 mL dose, i.e. essentially 'potassium- free'.
This medicinal product contains less than 1 mmol sodium (23 mg) per 0.5 mL dose, that is to say essentially 'sodium- free'.
Simultaneous administration of Havrix with normal immunoglobulin does not influence the seroconversion rate to Havrix, however, it may result in a lower antibody titre. A similar effect could be observed with Havrix Junior Monodose.
Preliminary data on the concomitant administration of Havrix, at a dose of 720 ELISA units/mL, with recombinant hepatitis B virus vaccine suggests that there is no interference in the immune response to either antigen. Havrix Junior Monodose can be given concomitantly with monovalent and combination vaccines comprised of measles, mumps, rubella and varicella. When concomitant administration is considered necessary the vaccines must be given at different injection sites.
Havrix Junior Monodose must not be mixed with other vaccines in the same syringe.
Pregnancy
There are no or limited amount of data from the use of this vaccine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. The use of this vaccine may be considered during pregnancy, if necessary.
Breast-feeding
It is unknown whether this vaccine is excreted in human milk. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility
No fertility data are available.
No studies of the effects of Havrix Junior Monodose on the ability to drive and use machines have been performed. However, some of the effects mentioned under section 4.8 “Undesirable effects” may temporarily affect the ability to drive or use machines.
The safety profile presented below is based on data from more than 5300 subjects that participated in clinical trials, plus reactions observed through post-marketing surveillance. It should be noted that it was not possible to calculate the frequency of reactions from the post-marketing data, therefore the frequency is noted as “Not known”.
The most frequently reported reactions are pain and redness at site of injection (Havrix Monodose has reports in over 50% of doses, Havrix Junior Monodose has reports in 18.2% of doses overall). Swelling at the site of injection was the next most frequently reported reactions.
Frequencies per dose are defined as follows:
Very common:
≥ 1/10
Common:
≥ 1/100 to < 1/10
Uncommon:
≥ 1/1,000 to < 1/100
Rare:
≥ 1/10,000 to < 1/1,000
Very rare:
< 1/10,000
Not Known:
Cannot be estimated from the data available
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness
* refers to adverse reaction reported only for Havrix Monodose (1mL adult dose)
** refers to adverse reactions reported only for Havrix Junior Monodose (0.5mL children's dose)
# this adverse reaction was identified through post-marketing surveillance but was not observed in randomised controlled clinical trials. The frequency category of rare was estimated from a statistical calculation based on the total number of paediatric patients exposed to Havrix in randomised controlled clinical trials (n=4574).
System Organ Classes
Frequency
Adverse reaction
Infections and infestations
Uncommon
Upper respiratory tract infection*
Rhinitis*
Immune system disorders
Not known
Anaphylaxis
Allergic reactions including anaphylactoid reactions and mimicking serum sickness
Metabolism and nutrition disorders
Common
Appetite lost
Psychiatric disorders
Very common
Irritability**
Nervous system disorders
Very common
Headache (common with Havrix Junior Monodose formulation)
Common
Drowsiness**
Uncommon
Dizziness*
Rare
Hypoaesthesia
Paraesthesia
Not known
Convulsions
Guillain Barre Syndrome
Transverse myelitis
Neuralgic amyotrophy
Vascular disorders
Not known
Vasculitis
Gastrointestinal disorders
Common
Gastrointestinal symptoms*(rare with Havrix Junior Monodose formulation#)
Nausea
Diarrhoea (uncommon with Havrix Junior Monodose formulation)
Uncommon
Vomiting
Hepatobiliary disorders
Not known
Transient increase in liver function tests
Skin and subcutaneous tissue disorders
Uncommon
Rash**
Rare
Pruritus
Not known
Angioneurotic oedema
Erythema multiforme
Urticaria
Musculoskeletal and connective tissue disorders
Uncommon
Myalgia*
Musculoskeletal stiffness*
Not known
Arthralgia
General disorders and administration site conditions
Very common
Pain and redness at the injection site
Fatigue* (rare with Havrix Junior Monodose formulation#)
Common
Fever (≥ 37.5 °C)
Injection site reaction, such as swelling or induration (uncommon with Havrix Junior Monodose formulation)
Malaise
Uncommon
Influenza like illness*
Rare
Chills
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Cases of overdose have been reported during post-marketing surveillance. Adverse events reported following overdosage were similar to those reported with normal vaccine administration.
Ask anything about Havrix Junior Monodose Vaccine. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.